StoxBiocon vs Onesource Specialty Pharma: share price & financials comparison
NSE: BIOCON vs ONESOURCE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Biocon vs Onesource Specialty Pharma at a glance
Biocon (BIOCON) has a market capitalisation of ₹59,326 Cr, against ₹18,463 Cr for Onesource Specialty Pharma (ONESOURCE). Over the past year Biocon has returned -4.3%, compared with -12.2% for Onesource Specialty Pharma. Biocon earns a higher return on equity (1.3% vs -0.0%). Biocon comes out ahead on size, valuation and profitability. Onesource Specialty Pharma comes out ahead on growth, financial health, momentum and technicals. Across the scored metrics below, Biocon leads on 5 and Onesource Specialty Pharma on 7. On StoxGud's 10-point checklist, Biocon scores 2/10 and Onesource Specialty Pharma scores 4/10.
| Metric | Biocon | Onesource Specialty Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹59,326 Cr | ₹18,463 Cr |
| Revenue (latest FY) | ₹16,927 Cr | ₹1,422 Cr |
| Net profit (latest FY) | ₹386 Cr | ₹-74 Cr |
| Valuation | ||
| P/E | 131.2 | — |
| P/B | 1.70 | 3.12 |
| Dividend yield | 0.15% | — |
| Profitability | ||
| Return on equity | 1.3% | 0.0% |
| Net profit margin | 2.6% | -0.1% |
| Operating margin | 20.3% | 23.5% |
| Growth | ||
| Revenue growth (YoY) | +2.2% | +37.4% |
| Net profit growth (YoY) | -51.1% | +687.0% |
| Revenue CAGR (multi-year) | +19.0% | — |
| Financial health | ||
| Debt to equity | 0.43 | 0.25 |
| Momentum | ||
| 1-month return | +3.7% | +10.3% |
| 1-year return | -4.3% | -12.2% |
| 3-year CAGR | +17.0% | — |
| 5-year CAGR | +0.1% | — |
| 10-year CAGR | +9.8% | — |
| Distance from 52W high | -17.4% | -13.8% |
| Technicals | ||
| RSI (14) | 76 | 82 |
| Price vs 200-day avg | -6.7% | +4.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Biocon | Onesource Specialty Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 2/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Biocon or Onesource Specialty Pharma?
Biocon has a market cap of ₹59,326 Cr and Onesource Specialty Pharma has a market cap of ₹18,463 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Biocon or Onesource Specialty Pharma?
Biocon did better: Biocon returned -4.3% and Onesource Specialty Pharma returned -12.2% over one year.
What is the difference between Biocon and Onesource Specialty Pharma?
Both are NSE-listed companies in Healthcare. Biocon is about 3.2 times the size of Onesource Specialty Pharma by market cap. In the latest financial year Biocon reported revenue of ₹16,927 Cr and Onesource Specialty Pharma ₹1,422 Cr. Operating margin is 20.3% for Biocon and 23.5% for Onesource Specialty Pharma. Debt to equity is 0.43 for Biocon and 0.25 for Onesource Specialty Pharma.
Which is better, Biocon or Onesource Specialty Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Biocon leads on 5 and Onesource Specialty Pharma on 7. Biocon is ahead on size, valuation and profitability. Onesource Specialty Pharma is ahead on growth, financial health, momentum and technicals. On StoxGud's rules-based checklist Biocon scores 2/10 and Onesource Specialty Pharma scores 4/10. This is information, not advice: consult a SEBI-registered adviser before investing.